Skip to main content
. Author manuscript; available in PMC: 2023 Dec 26.
Published in final edited form as: Leukemia. 2022 Dec 22;37(3):560–570. doi: 10.1038/s41375-022-01798-5

Figure 5. Effect of CXCL12 KO modestly on quizartinib response.

Figure 5.

(A) Experimental design for single-agent quizartinib (AC220) treatment in CXCL12-WT and CXCL12-KO AML mice. (B) WBC counts (left) and spleen weights (right) and (C) HSPC (left) and ST-HSC numbers (right) in BM of CXCL12-WT or CXCL12-KO mice transplanted with AML BM and treated with vehicle control or single-agent quizartinib. Significance values: *p<0.05; **p<0.01; ***p<0.001. Results represent mean ± SEM of multiple replicates.